Summary Marketline's Bruker Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bruker Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports off...
A director at Danaher Corp sold/sold after exercising options 34,688 shares at 236.587USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Summary Bruker Corp - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bruker Corp (Bruker) designs, manufactures and sells scientific instruments, and analytical and diagnostic solutions. The company's product portfolio includes mass spectrometry technologies, microtomography...
Moody's Investors Service commented that Danaher Corporation's announcement that it will acquire Abcam plc for approximately $5.7 billion is positive for the Danaher's business profile and growth rates. There is no impact on Danaher's A3 rating or its stable outlook. For additional information ple...
Our analysis of the order book leads us to believe that revenue guidance is almost impossible to hit without 20% revenue growth in Q423. Much more worryingly, mgmt admitted to adding 50% to capacity in terms of revenues which will start to come on stream in Q4, this year. When there is already excess capacity & SSB’s Q2 gross margin was the weakest in >5yrs driven by lower utilisation, the recent rally is a clear selling opportunity in our view. Today’s Danaher revenue guidance downgrade also do...
We have calculated the significant supply about to enter the biologics manufacturing space & analysed demand growth. Whilst the market assumes an improvement in utilisation from 2024, we forecast there will be significant overcapacity in the coming years resulting in even lower utilisation at an industry level. Our detailed bottom-up analysis shows that total mammalian cell supply is set to grow by 11% p.a. 2023-26 but demand is set to grow just 8% p.a. over the same period. However, much more c...
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.